



February 10, 2022

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001

**Subject: Press Release for unaudited Financial Results (Standalone and Consolidated)  
for the Quarter and Nine Months ended December 31, 2021**

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2021.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

**Rajat Kalra**  
Company Secretary and Legal Head



Encl: As above

Classification: Internal

**Dr. Lal PathLabs Limited records revenue of Rs 496.9 Cr in Q3 FY 2021-22**

New Delhi, India, February 10, 2022 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2021. The results includes Suburban Diagnostics wef 12<sup>th</sup> Nov’21, hence, not strictly comparable with previous year.

**Consolidated Performance Highlights: Q3 FY 2021-22 vs Q3 FY 2020-21**

**Revenue: Rs 496.9 Cr, a growth of 9.8%**

**Normalised EBITDA at Rs 141.8 Cr with margin at 28.5%**

**PBT at Rs 81.5 Cr with margin at 16.4%, and**

**PAT Rs 58.2 Cr with margin at 11.7%**

- Operating Revenue increased by 9.8% in Q3 FY22 to Rs. 496.9 Cr vs Rs 452.4 Cr in Q3 FY21
- Covid and Allied contributed 11.8% to Revenue in Q3 FY22 with 5.8 lacs RTPCR tests
- Normalised EBITDA (after adjustment for stock based compensation, CSR & One time acquisition cost) for Q3 FY22 is at Rs. 141.8 Cr (margins 28.5%) Vs Rs 144.6 Cr in the same quarter last year
- PBT is at Rs 81.5 Cr in Q3 FY22 (Normalised PBT\* at Rs 112.8 Cr, margins 22.7%) vs Rs 128.9 Cr. in Q3 last year
- Profit after Tax in Q3 FY22 (Normalised PAT\* at Rs 83.6 Cr, margins 16.8%) at Rs. 58.2 Cr as compared to Rs 95.9 Cr in Q3 last year

**Financial Overview (Consolidated) in Rs Cr**

Particulars	Q3			YTD December		
	FY22	FY21	Gr %	FY22	FY21	Gr %
<b>Revenue</b>	<b>496.9</b>	<b>452.4</b>	<b>9.8%</b>	<b>1601.9</b>	<b>1150.3</b>	<b>39.3%</b>
Non Covid	438.1	341.9	28.1%	1271.6	883.1	44.0%
Covid & Allied	58.8	110.5	-46.8%	330.3	267.3	23.6%
<b>Expenditure</b>	<b>387.6</b>	<b>313.6</b>	<b>23.6%</b>	<b>1162.2</b>	<b>836.1</b>	<b>39.0%</b>
<b>EBITDA</b>	<b>109.2</b>	<b>138.7</b>	<b>-21.3%</b>	<b>439.6</b>	<b>314.3</b>	<b>39.9%</b>
EBITDA Margins	22.0%	30.7%		27.4%	27.3%	
RSU & CSR cost	9.3	5.8		30.1	18.8	
One off Acquisition Cost	23.3	0.0		23.3	0.0	
<b>Normalised EBITDA</b>	<b>141.8</b>	<b>144.6</b>	<b>-1.9%</b>	<b>493.0</b>	<b>333.1</b>	<b>48.0%</b>
EBITDA Margins	28.5%	32.0%		30.8%	29.0%	
Other Income (Net)	3.0	9.6		22.2	26.2	
Depreciation Cost	30.7	19.4		70.4	56.9	
<b>PBT*</b>	<b>81.5</b>	<b>128.9</b>	<b>-36.8%</b>	<b>391.4</b>	<b>283.6</b>	<b>38.0%</b>
Margins	16.4%	28.5%		24.4%	24.7%	
<b>PAT*</b>	<b>58.2</b>	<b>95.9</b>	<b>-39.3%</b>	<b>288.2</b>	<b>211.4</b>	<b>36.4%</b>
Margins	11.7%	21.2%		18.0%	18.4%	
<b>EPS</b>	<b>6.93</b>	<b>11.44</b>	<b>-39.4%</b>	<b>34.27</b>	<b>25.23</b>	<b>35.8%</b>
<b>Normalised PBT</b>	<b>112.8</b>	<b>128.9</b>	<b>-12.6%</b>	<b>422.7</b>	<b>283.6</b>	<b>49.0%</b>
Margins	22.7%	28.5%		26.4%	24.7%	
<b>Normalised PAT</b>	<b>83.6</b>	<b>95.9</b>	<b>-12.8%</b>	<b>313.6</b>	<b>211.4</b>	<b>48.4%</b>
Margins	16.8%	21.2%		19.6%	18.4%	

\*Normalised PBT and PAT are excluding one time acquisition cost and notional depreciation on consolidation of Suburban.



## About Dr. Lal PathLabs Limited

---

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2021 the company has 231 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,705 Patient Service Centers (PSCs) and 9,247 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

## Contact Details

---

Ved Prakash Goel  
Group Chief Financial Officer  
*Dr. Lal PathLabs Limited*

+91 124 3016500  
[cfo@lalpathlabs.com](mailto:cfo@lalpathlabs.com)

Rakshit Tewari/Gargi Mukherjee  
*Adfactors PR*

+91 9871154558  
[rakshit.tewari@adfactorspr.com](mailto:rakshit.tewari@adfactorspr.com)  
[gargi.mukherjee@adfactorspr.com](mailto:gargi.mukherjee@adfactorspr.com)

For further information on Dr. Lal PathLabs see [www.lalpathlabs.com](http://www.lalpathlabs.com)

---

## Safe Harbour

---

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.